References
- Cimpean AM, Raica M, Encica S, Cornea R, Bocan V. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 2008; 190: 238–45
- Bedano PM, Perkins S, Burns M, Kessler K, Nelson R, Schneider BP, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2008; 26(Suppl), (Abstract 19087)
- Isambert N, Freyer G, Zanetta S, Falandry C, Soussan Lazard K, Fumoleau P. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: Preliminary results. J Clin Oncol 2008; 26(Suppl), (Abstract 3599)
- Fiedler, WM, Giaccone, G, Lasch, P, Van der Horst, I, Brega, NM, Raber, S, , et al. Phase I trial of SU014813 in patients (pts) with advanced solid malignancies. J Clin Oncol ( Meeting Abstracts). 2007;25(18 Suppl):3521.
- Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25: 2369–76
- Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. New Engl J Med 2008; 359: 31–42